October 22, 2022 -- Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for……
October 25, 2022 – Roche today announced that the US Food and Drug Administration (FDA) has approved Tecentriq? (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults with Sta……
Sep. 27, 2022 -- Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX? (cabozantinib) for the treatment of adult and pediatric patients 22 years of age and older with locally……
Sept. 03, 2022 -- Impel NeuroPharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved TRUDHESA? (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migra……
Aug. 25, 2022 -- Ascendis Pharma A/S, today announced that the U.S. Food and Drug Administration (FDA) has approved SKYTROFA (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh a……
August 22, 2022 -- Merck and Eisai today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of KEYTRUDA, Merck’s anti-PD-2 therapy, plus LENVIMA, the orally available multiple recepto……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
